Literature DB >> 12776163

Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization.

J W B Bainbridge1, A Mistry, K Binley, M De Alwis, A J Thrasher, S Naylor, R R Ali.   

Abstract

Recombinant AAV vectors mediate efficient and sustained transgene expression in retinal tissues and offer a powerful approach to the local, sustained delivery of angiostatic proteins for the treatment of ocular neovascular disorders. The application of such strategies may also require regulated gene expression to minimize the potential for unwanted adverse effects. In this study, we have evaluated the effect of a hypoxia-responsive element (HRE) on the kinetics of recombinant adeno-associated (rAAV)-mediated reporter gene expression in murine models of retinal and choroidal neovascularization. In murine ischaemia-induced retinal neovascularization, intravitreal delivery of rAAV.HRE.GFP results in reporter gene expression specifically at sites of vascular closure during the period of active neovascularization and not after vector delivery in normal controls. In murine laser-induced choroidal neovascularization, subretinal delivery of rAAV.HRE.GFP results in reporter gene expression at sites of active neovascularization but not elsewhere or after vector delivery in normal controls. HRE-driven gene expression offers an attractive strategy for the targeted and regulated delivery of angiostatic proteins to the retina in the management of neovascular disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12776163     DOI: 10.1038/sj.gt.3301945

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  5 in total

1.  Hypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease.

Authors:  Howard M Prentice; Manas R Biswal; C Kathleen Dorey; Janet C Blanks
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-01       Impact factor: 4.799

2.  A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization.

Authors:  Manas R Biswal; Howard M Prentice; C Kathleen Dorey; Janet C Blanks
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-06       Impact factor: 4.799

3.  Synaptic pathology in retinoschisis knockout (Rs1-/y) mouse retina and modification by rAAV-Rs1 gene delivery.

Authors:  Yuichiro Takada; Camasamudram Vijayasarathy; Yong Zeng; Sten Kjellstrom; Ronald A Bush; Paul A Sieving
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08       Impact factor: 4.799

4.  Cell-specific gene therapy driven by an optimized hypoxia-regulated vector reduces choroidal neovascularization.

Authors:  Manas R Biswal; Howard M Prentice; George W Smith; Ping Zhu; Yao Tong; C Kathleen Dorey; Alfred S Lewin; Janet C Blanks
Journal:  J Mol Med (Berl)       Date:  2018-08-13       Impact factor: 4.599

5.  In vivo cellular imaging of various stress/response pathways using AAV following axonal injury in mice.

Authors:  Kosuke Fujita; Koji M Nishiguchi; Yu Yokoyama; Yusuke Tomiyama; Satoru Tsuda; Masayuki Yasuda; Shigeto Maekawa; Toru Nakazawa
Journal:  Sci Rep       Date:  2015-12-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.